Product
AXT107
Aliases
AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg, Gersizangatide
3 clinical trials
3 indications
Indication
Macular Edema (DME)Indication
Age-Related Macular DegenerationClinical trial
Phase 1/2a Study of the Safety and Bioactivity of AXT-107 in Subjects With Diabetic Macular Edema (DME)Status: Terminated, Estimated PCD: 2022-10-01
Clinical trial
Phase 1/2a Study of the Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)Status: Terminated, Estimated PCD: 2022-10-01
Clinical trial
Phase 1/2a Study of the Safety and Bioactivity of AXT107 Injected Suprachoroidally in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)Status: Active (not recruiting), Estimated PCD: 2025-03-01